• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓增殖性肿瘤的遗传复杂性

Genetic complexity of myeloproliferative neoplasms.

作者信息

Kralovics R

机构信息

Center for Molecular Medicine (CeMM), Austrian Academy of Sciences, Vienna, Austria.

出版信息

Leukemia. 2008 Oct;22(10):1841-8. doi: 10.1038/leu.2008.233. Epub 2008 Aug 28.

DOI:10.1038/leu.2008.233
PMID:18754034
Abstract

Oncogenic mutations in JAK2 and MPL genes have recently been identified in myeloproliferative neoplasms (MPNs). In addition to these mutations, cytogenetic aberrations are frequently present at diagnosis but their role in the pathogenesis remains unclear. Two models of MPN pathogenesis have recently emerged based on either a single-hit or a multi-hit concept. The first model proposes that the acquisition of JAK2 mutations is the disease-initiating event, causing both the onset of disease phenotype and establishment of clonal hematopoiesis. The second model postulates the existence of 'pre-JAK2' mutations that establish clonal hematopoiesis before acquisition of JAK2 mutations and onset of disease phenotype. In this review, the two models have been critically evaluated in the context of the latest findings. At present, neither of the two models can be universally applied to all MPN patients due to their genetic heterogeneity. It is likely that the disease pathogenesis in some patients follows the first, and in other patients, the second model. Thus, the somatic mutations in MPN do not seem to be acquired in a predetermined order as seen in other malignancies, but occur randomly. Furthermore, the role of uniparental disomy in MPN and certain aspects of MPN therapy are discussed.

摘要

近期在骨髓增殖性肿瘤(MPN)中发现了JAK2和MPL基因的致癌突变。除了这些突变外,细胞遗传学异常在诊断时也经常出现,但其在发病机制中的作用仍不清楚。基于单次打击或多次打击概念,最近出现了两种MPN发病机制模型。第一种模型提出,JAK2突变的获得是疾病起始事件,导致疾病表型的出现和克隆性造血的建立。第二种模型假定存在“前JAK2”突变,这些突变在获得JAK2突变和疾病表型出现之前就建立了克隆性造血。在这篇综述中,结合最新研究结果对这两种模型进行了批判性评估。目前,由于其基因异质性,这两种模型都不能普遍适用于所有MPN患者。某些患者的疾病发病机制可能遵循第一种模型,而其他患者则遵循第二种模型。因此,MPN中的体细胞突变似乎不像在其他恶性肿瘤中那样按预定顺序获得,而是随机发生的。此外,还讨论了单亲二体在MPN中的作用以及MPN治疗的某些方面。

相似文献

1
Genetic complexity of myeloproliferative neoplasms.骨髓增殖性肿瘤的遗传复杂性
Leukemia. 2008 Oct;22(10):1841-8. doi: 10.1038/leu.2008.233. Epub 2008 Aug 28.
2
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.骨髓增殖性肿瘤中的JAK2和MPL突变:发现与科学
Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28.
3
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.JAK2 V617F 及其他:遗传学和异常信号在骨髓增殖性肿瘤发病机制中的作用。
Expert Rev Hematol. 2010 Jun;3(3):323-37. doi: 10.1586/ehm.10.28.
4
Myeloproliferative neoplasms: A decade of discoveries and treatment advances.骨髓增殖性肿瘤:十年的发现和治疗进展。
Am J Hematol. 2016 Jan;91(1):50-8. doi: 10.1002/ajh.24221.
5
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.JAK2 V617F时代真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化的诊断与管理
Clin Adv Hematol Oncol. 2009 May;7(5):334-42.
6
Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs).
Leukemia. 2008 Oct;22(10):1818-27. doi: 10.1038/leu.2008.218. Epub 2008 Aug 28.
7
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?慢性炎症作为原发性血小板增多症、真性红细胞增多症和骨髓纤维化中突变的促进因素。一种人类炎症模型与癌症发展有关?
Leuk Res. 2013 Feb;37(2):214-20. doi: 10.1016/j.leukres.2012.10.020. Epub 2012 Nov 20.
8
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.骨髓增殖性肿瘤中JAK2V617F存在或等位基因负担的临床相关性:一项批判性重新评估。
Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Epub 2008 May 22.
9
Somatic mutations of calreticulin in myeloproliferative neoplasms.髓系增殖性肿瘤中的钙网织蛋白体细胞突变。
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
10
The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms.体细胞突变获得的时间顺序和差异决定了 JAK2 阳性骨髓增殖性肿瘤的临床行为。
Anticancer Res. 2019 Nov;39(11):6273-6282. doi: 10.21873/anticanres.13837.

引用本文的文献

1
Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms.用于早期检测费城阴性骨髓增殖性肿瘤的分子研究。
Int J Mol Sci. 2023 Aug 11;24(16):12700. doi: 10.3390/ijms241612700.
2
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.JAK2 或 CALR 突变骨髓增殖性肿瘤中疾病起始干细胞的表型特征。
Am J Hematol. 2023 May;98(5):770-783. doi: 10.1002/ajh.26889. Epub 2023 Mar 9.
3
The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance.
原发性骨髓纤维化的遗传学基础及其临床意义。
Int J Mol Sci. 2020 Nov 24;21(23):8885. doi: 10.3390/ijms21238885.
4
Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.阐明骨髓增殖性肿瘤分子发病机制的进展及其在治疗决策中的应用。
Int J Hematol. 2020 Feb;111(2):182-191. doi: 10.1007/s12185-019-02778-9. Epub 2019 Nov 18.
5
Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells.骨髓增殖性肿瘤的血清会刺激造血干细胞和祖细胞。
PLoS One. 2018 May 31;13(5):e0197233. doi: 10.1371/journal.pone.0197233. eCollection 2018.
6
MYC Deregulation in Primary Human Cancers.原发性人类癌症中的MYC失调
Genes (Basel). 2017 May 25;8(6):151. doi: 10.3390/genes8060151.
7
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.骨髓增殖性肿瘤与JAK/STAT信号通路:概述
Rev Bras Hematol Hemoter. 2015 Sep-Oct;37(5):348-53. doi: 10.1016/j.bjhh.2014.10.001. Epub 2015 Jun 9.
8
JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.原发性骨髓纤维化患者中JAK2外显子14跳跃:一种受JAK2-V617F等位基因负担调节的次要剪接变体
PLoS One. 2015 Jan 24;10(1):e0116636. doi: 10.1371/journal.pone.0116636. eCollection 2015.
9
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.多突变晚期系统性肥大细胞增多症中髓系前体细胞的分子谱分析确定 KIT D816V 为一个独特的晚期事件。
Leukemia. 2015 May;29(5):1115-22. doi: 10.1038/leu.2015.4. Epub 2015 Jan 8.
10
Back to biology: new insights on inheritance in myeloproliferative disorders.回归生物学:骨髓增殖性疾病遗传方面的新见解。
Curr Hematol Malig Rep. 2014 Dec;9(4):311-8. doi: 10.1007/s11899-014-0232-3.